Search Results for “EC” – Page 65 – media

Goldman Sachs Closes $650M Fund to Invest in ‘Golden Era’ of Biotech Innovation

Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm. By FRANK VINLUAN Goldman Sachs Asset Management has expanded to biotech investments in recent years. The investment firm is now preparing to ramp up its investment activity in the sector with a new $650 million fund, its first dedicated to the life sciences. Goldman on Wednesday announced the final close of the new fund, called West Street Life Sciences I. About $90 million from this fund has already been committed to five biotech companies in its portfolio: MOMA Therapeutics, Nested Therapeutics, TORL Biotherapeutics, Septerna, and Rapport Therapeutics. With the new fund, Goldman said the focus will be on growth-oriented private equity investments in the life sciences, which it’s defining as early- to mid-stage ...
- Source: drugdu
- 153
- January 5, 2024
Nearly three million people received urgent NHS cancer checks in 2023

The number of people getting tested over the last decade has increased by 133% The NHS has announced a new analysis showing its highest year on record for providing urgent cancer checks over the last year. Almost three million people in the UK received cancer checks between November 2022 and October 2023. In alignment with the health service’s goal of catching cancer earlier, the new analysis has shown a 133% increase in the number of people getting checked for cancer over the last decade. Between November 2022 and October 2023, over 2.9 million people were seen for urgent cancer checks, an increase of 147,960 people between 2021 and 2022. In October alone, the NHS saw the highest month on record for cancer checks, as well as 269,492 urgent referrals and 192,889 people who received an all-clear or definitive cancer diagnosis. In addition to this, the NHS has made major progress ...
- Source: drugdu
- 129
- January 5, 2024
Automated Liquid Biopsy Detects Brain Tumor Cells in Children

Brain and other central nervous system (CNS) cancers are the primary cause of cancer-related deaths in children, ranking as the second most prevalent form of childhood cancer following leukemia. For treating CNS tumors, healthcare professionals traditionally rely on a series of magnetic resonance imaging (MRI) scans to gauge the effectiveness of treatments such as surgery, chemotherapy, and radiation. However, MRI scans have limitations, particularly in detecting microscopic diseases that might signal residual or recurring cancer cells. To bridge this gap, scientists have been on a quest to identify reliable, tumor-specific biomarkers. Prior research in adults has demonstrated that primary tumors release circulating tumor cells (CTCs) into the bloodstream, suggesting that CTCs could serve as dependable biomarkers for CNS tumors. A recent study conducted by researchers at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) aimed to determine the effectiveness of a liquid biopsy tool designed to detect ...
- Source: drugdu
- 168
- January 4, 2024
Beyfortus® Approved in China for the Prevention of Respiratory Syncytial Virus Infections in Infants

On January 2, 2024, AstraZeneca and Sanofi announced that the long-acting monoclonal antibody Beyfortus® (Nirsevimab/nisevizumab) has been officially approved for marketing by the State Drug Administration of China (SDA) for the prevention of Lower Respiratory Tract Infections (LRTIs) caused by Respiratory Syncytial Virus (RSV) in newborns and infants. The drug is indicated for newborns and infants who are entering or born during the first season of RSV infection. Nisevizumab is expected to be available in China during the 2024-2025 RSV infection season. Nisevizumab is the first and only* approved prophylaxis in China to protect the broader infant population against RSV infection, covering healthy term infants, preterm infants, and infants vulnerable to serious RSV infection due to specific health conditions. Nisevizumab was approved in China based on the results of three pivotal clinical trials and the Chinese clinical development program. For all clinical trial endpoints, a single injection of nisevizumab demonstrated ...
- Source: drugdu
- 125
- January 4, 2024
Tsinghua University, in collaboration with Minhai Biotechnology, discovers a novel immunoprotective mechanism for vaccine clearance of pathogenic bacteria

Vaccine immunization has dramatically reduced the morbidity and mortality of invasive bacterial infectious diseases such as bloodstream infections. Although a large number of studies have demonstrated that immune protection requires vaccine-induced antibody production, human beings still lack a clear understanding of the cellular and molecular mechanisms of how vaccines provide immune protection. The current international consensus is that vaccines provide immune protection by activating phagocytes in the spleen and blood circulation to remove pathogens that invade the bloodstream. Recently, Jingren Zhang’s group and Linqi Zhang’s group at Tsinghua University School of Medicine, together with Haifa Zheng’s group at Beijing Minhai Biotechnology Co., Ltd, published a paper in Science Translational Medicine titled “Liver macrophages and sinusoidal endothelial cells The research paper, entitled Liver macrophages and sinusoidal endothelial cells execute vaccine-elicited capture of invasive bacteria, reveals that the liver is the main organ that executes vaccine-elicited immunoprotection, and elucidates the molecular mechanism ...
- Source: drugdu
- 121
- January 4, 2024
World Health Organization adds second malaria vaccine to prequalification list

The World Health Organization (WHO) has said it has added a new malaria vaccine to its list of prequalified vaccines, marking a “significant milestone” in the prevention of the mosquito-borne disease. R21/Matrix-M, developed by the University of Oxford and the Serum Institute of India, is now the second malaria vaccine to be prequalified by the organisation following its prequalification of the RTS,S/AS01 vaccine in July 2022. Malaria places a particularly high burden on the African Region, where nearly half a million children die from the disease every year. Despite high demand, WHO outlined that the available supply of RTS,S has been limited and expects the addition of R21 to result in sufficient vaccine supply for children living in areas where malaria is a significant public health risk. Dr Kate O’Brien, director of WHO’s department of immunisation, vaccines and biologicals, said the decision marked “a huge stride in global health”. “This ...
- Source: drugdu
- 157
- January 4, 2024
Placental Swabs Found Most Effective for Detection of Maternal Sepsis

Over half of maternal deaths occurring in hospitals are attributed to sepsis, a critical condition where an infection spreads beyond local tissue containment, leading to organ failure. Maternal or perinatal sepsis is a significant health concern globally, affecting more than 20 million women and resulting in approximately 17,000 deaths each year. Identifying the infectious agents responsible for these cases is often a complex task. While blood cultures are the preferred diagnostic method, they frequently yield low positive results. Other specimens like vaginal swabs have limited clinical usefulness, and obtaining microbiological cultures from the uterine cavity for antimicrobial guidance is typically challenging. Now, a new study of microbiology specimens used to investigate maternal sepsis has demonstrated that placental swabs could play a vital role in informing antimicrobial therapy decisions. The study performed by researchers from the University of Limerick (Limerick, Ireland) involved the analysis of nearly 2,000 specimens collected over five ...
- Source: drugdu
- 158
- January 3, 2024
CD3/BCMA/GPRC5D Tri-Specific Antibody MBS314 Approved in Phase I/II Clinical Trial for the Treatment of Multiple Myeloma

Recently, MBS314, an innovative tri-specific antibody product developed by Beijing Mabworks Biotech Company Limited (hereinafter referred to as “Mabworks”) in collaboration with Kangyuan Botron Biotechnology (Beijing) Limited, has obtained the Notice of Approval for Clinical Trial of Drugs issued by the State Drug Administration of the People’s Republic of China (SDA), which authorizes the conduct of Phase I/II clinical trial for the treatment of multiple myeloma. Myeloma. MBS314 is a new mechanism of tri-specific antibody targeting CD3/BCMA/GPRC5D for the treatment of multiple myeloma.MBS314 has a differentiated CD3 binding epitope, which is able to achieve low-affinity but long-lasting activation and killing effect with T-cells, with better safety; at the same time, it binds BCMA and GPRC5D with high affinity, which is able to overcome BCMA and GPRC5D tumor cell killing effect in the body of the patient. At the same time, the high affinity combination of BCMA and GPRC5D can overcome ...
- Source: drugdu
- 137
- January 3, 2024
‘Disappointed’ IQVIA hit by judge’s decision to uphold FTC’s block of its DeepIntent buyout

A U.S. judge has upheld the Federal Trade Commission’s (FTC) decision to block IQVIA’s long-running attempt to buy the owner of pharma digital ad specialist DeepIntent. The long-running saga centers on IQVIA, the leading biopharma data provider, and its attempt to snap up Propel Media for its DeepIntent business. IQVIA tried to buy Propel back in 2022 (financials details remain unknown), but the FTC last year put a block on the deal, arguing that it would inevitably give IQVIA a market-leading position in advertising for healthcare products, namely prescription drugs, to doctors and other healthcare professionals. According to the official complaint filed by the FTC in 2023, the merger would result in a “heightened motivation” for IQVIA to withhold critical information, hindering competition among rival companies and potential new entrants. Additionally, the complaint asserts that the merger would lead to decreased market competitiveness. The company is one of the world’s ...
- Source: drugdu
- 87
- January 3, 2024
Recursion counts the costs of 2023 in…coffee?

Many biopharmas like to take a moment at the end of the year to reflect. Often, these reflections take the form of investments made or received, research undertaken, or drugs approved. For AI biotech Recursion Pharmaceuticals, however, (and this also strikes true for biopharma journalists), the focus of the past 12 months was: Coffee consumption. Posting on X (formerly Twitter), the biotech wrote: “At Recursion, our daily grind goes beyond experiments and algorithms—it’s fueled by a serious love for coffee. We’re big fans of data, so we crunched the numbers to find out how much java powered our teams.” Those numbers are, even for an editor, impressive. The team has a whole drank 5,523,490 mg of caffeine via 58,142 cups of coffee. Dark roast was the roast of choice, with 830 lbs consumed over the year, compared to 385 lbs for light roast, and 391 lbs for decaf. It was ...
- Source: drugdu
- 149
- January 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.